A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)

Inclusion Criteria:

• Participant must be >= 18 years of age inclusive, at the time of signing theinformed consent form

• Participants with a clinical indication for a contrast-enhanced MRI (includingmagnetic resonance angiography [MRA]), with any approved standard of caremacrocyclic GBCA with proven efficacy, safety and tolerability in clinical routineCE-MRI/MRA (gadobutrol, gadoterate meglumine/ gadoteric acid or gadoteridol) that isused at the site for the indication, with known or suspected pathology of any bodyregion, e.g. head and neck (except central nervous system [CNS]), thorax (includinge.g. breast, heart, chest wall), abdomen (including e.g. liver, kidney, pancreas),pelvis (including e.g. prostate, uterus, ovaries), extremities (including upper andlower.

• Participants who can undergo study-related procedures, including 2 contrast-enhancedMRI examinations (one with gadoquatrane and one with a comparator macrocyclic GBCA),as per participant and Investigator's judgement

• Contraceptive use by female participants should be consistent with local regulationsregarding the methods of contraception for those participating in clinical studies.A female participant is eligible to participate if she is not pregnant orbreastfeeding, and one of the following conditions applies: Is a woman ofnonchildbearing potential (WONCBP) OR Is a woman of childbearing potential (WOCBP)and using an acceptable contraceptive method during the study intervention period (at a minimum of 24 hours after the last dose of study intervention).

Exclusion Criteria:

• Considered clinically unstable or has a concurrent/concomitant condition that maysignificantly alter image comparability between the 2 study MRIs or between studyparameters (e.g. safety, pharmacokinetics [PK] parameters) or would not allowparticipation for the full planned study period, in the judgement of theinvestigator

• Participants presenting with severe renal insufficiency, defined as an estimatedglomerular filtration rate (eGFR) < 30 mL/min/1.73 m^2, derived from a serum orplasma creatinine sample obtained within 48 hours prior to the first contrast agentinjection in the study

• Participants with acute kidney injury (i.e., acute renal failure), regardless ofeGFR

• History of moderate to severe allergic-like reaction to any GBCA

• Bronchial asthma considered unstable or who have had recent modification to theirmedical therapy

• Receipt of any contrast agent < 72 h prior to the study MRIs or planned to receiveany contrast agent during the trial until 24 h +/- 4 h after the second study MRI

• Planned or expected interventional diagnostic or therapeutic procedure (e.g. biopsyor surgery in the region of interest) or change in treatment (e.g. start ofchemotherapy or antiangiogenic therapy, significant change in corticosteroids dose)that may significantly alter image comparability between the 2 MRIs or other studyparameters (i.e. safety/adverse events [AEs] [e.g. confounding AEs or safety eventsdue to surgery or chemotherapy], PK parameters), from the first study MRI up to 24 hafter the second study MRI

• Has received any investigational product within 30 days, or within 5 times half-lifeof the investigational product, whatever is shorter, prior to or concurrent withthis study

• Contraindications to the administration of macrocyclic GBCAs (depending on localproduct label), or history of adverse reaction to gadoquatrane

• Any contraindication to MRI examinations based on institution policy andinvestigator's clinical judgement (e.g. some metallic implants or active implants)